Advertisement

Journal of Gastroenterology

, Volume 46, Issue 2, pp 212–221 | Cite as

The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma

  • Satoru Hagiwara
  • Masatoshi KudoEmail author
  • Kazuomi Ueshima
  • Hobyung Chung
  • Mami Yamaguchi
  • Masahiro Takita
  • Seiji Haji
  • Masatomo Kimura
  • Tokuzo Arao
  • Kazuto Nishio
  • Ah-Mee Park
  • Hiroshi Munakata
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Combination therapy with the oral fluoropyrimidine anticancer drug S1 and interferon is reportedly effective for the treatment of advanced hepatocellular carcinoma (HCC), but selection criteria for this therapy have not been clarified. In this study, we attempted to identify factors predicting the effectiveness of this combination therapy.

Methods

Pathological specimens of HCC were collected before treatment from 31 patients with advanced HCC who underwent S1+ pegylated-interferon (PEG-IFN) α-2b therapy between January 2007 and January 2009. In these pathological specimens, the expression levels of CD133, thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), and interferon-receptor 2 (IFNR2) proteins were determined by Western blot assay. The presence or absence of p53 gene mutations was determined by direct sequencing. The relationships between these protein expression levels and the response rate (RR), progression-free survival (PFS), and overall survival (OS) were evaluated.

Results

The CD133 protein expression level was significantly lower in the responder group than in the nonresponder group. Comparing the PFS and OS between high- and low-level CD133 expression groups (n = 13 and 18, respectively) revealed that both parameters were significantly prolonged in the latter group. The expression levels of TS, DPD, and IFNR2 protein and the presence of p53 gene mutations did not correlate with the RR.

Conclusions

CD133 was identified as a predictor of the therapeutic effect of S1+ PEG-IFN α-2b therapy against advanced HCC.

Keywords

5-Fluorouracil Pegylated interferon CD133 Cancer stem cell Hepatocellular carcinoma 

Abbreviations

5FU

5-Fluorouracil

DPD

Dihydropyrimidine dehydrogenase

HCC

Hepatocellular carcinoma

IFNR2

Interferon-receptor 2

NR

Nonresponder

OS

Overall survival

PD

Progressive disease

PEG-IFN

Pegylated interferon

PFS

Progression-free survival

PR

Partial response

RR

Response rate

SD

Stable disease

TS

Thymidylate synthase

Notes

Acknowledgments

The protocol of this study was approved by the Medical Committee of Kinki University of Medicine.

Conflict of interest

None.

References

  1. 1.
    Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, et al. Natural history of compensated cirrhosis in the Child–Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol. 2006;78:459–65.CrossRefPubMedGoogle Scholar
  2. 2.
    Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987;47:4967–72.PubMedGoogle Scholar
  3. 3.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMedGoogle Scholar
  4. 4.
    Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Sato M, Watanabe Y, Ueda S, Iseki S, Abe Y, Sato N, et al. Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology. 1996;110:1507–14.CrossRefPubMedGoogle Scholar
  6. 6.
    Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer. 2001;91:1342–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602–6.PubMedGoogle Scholar
  9. 9.
    Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, et al. Preclinical antitumor efficacy of S-1; a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 1998;13:693–8.PubMedGoogle Scholar
  10. 10.
    Cao S, Lu K, Tóth K, Slocum HK, Shirasaka T, Rustum YM. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. Clin Cancer Res. 1999;5:267–74.PubMedGoogle Scholar
  11. 11.
    Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002;94:435–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Nakamura M, Nagano H, Marubashi S, Miyamoto A, Takeda Y, Kobayashi S, et al. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer. 2008;112:1765–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Ueshima K, Kudo M, Nagai T, Tatsumi C, Ueda T, Takahashi S, et al. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology. 2008;75:106–13.CrossRefPubMedGoogle Scholar
  14. 14.
    Uka K, Aikata H, Mori N, Takaki S, Kawakami Y, Azakami T, et al. Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastasis. Oncology. 2008;75:8–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.CrossRefPubMedGoogle Scholar
  17. 17.
    O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.CrossRefPubMedGoogle Scholar
  19. 19.
    O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;13:994–1004.CrossRefGoogle Scholar
  20. 20.
    Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004;64:1403–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer. 2003;104:790–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Mcleod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. Br J Cancer. 1998;77:461–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology. 1999;29:1708–17.CrossRefPubMedGoogle Scholar
  24. 24.
    Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer. 2005;93:557–64.CrossRefPubMedGoogle Scholar
  25. 25.
    Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signaling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516–23.CrossRefPubMedGoogle Scholar
  26. 26.
    Hagiwara S, Kudo M, Nakatani T, Sakaguchi Y, Nagashima M, Fukuta N, et al. Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. Br J Cancer. 2007;97:1532–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, et al. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res. 2004;10:7884–95.CrossRefPubMedGoogle Scholar
  28. 28.
    Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997;90:5013–21.PubMedGoogle Scholar
  29. 29.
    Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84.CrossRefPubMedGoogle Scholar
  30. 30.
    Zou GM. Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. J Cell Physiol. 2008;217:598–604.CrossRefPubMedGoogle Scholar
  31. 31.
    Sell S, Leffert HL. Liver cancer stem cells. J Clin Oncol. 2008;26:2800–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542–56.CrossRefPubMedGoogle Scholar
  33. 33.
    Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351:820–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Song W, Li H, Tao K, Li R, Song Z, Zhao Q, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008;62:1212–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA. 2002;99:16220–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458:780–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Kawabata S, Oka M, Soda H, Shinozawa K, Nakatomi K, Tsurutani J. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res. 2003;9:3052–7.PubMedGoogle Scholar
  38. 38.
    Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27:1749–58.CrossRefPubMedGoogle Scholar
  39. 39.
    Peters GJ, van der Wilt CL, van Triest B, Codacci-Pisanelli G, Johnston PG, van Groeningen CJ, et al. Thymidylate synthase and drug resistance. Eur J Cancer. 1995;31:1299–305.CrossRefGoogle Scholar
  40. 40.
    Oie S, Ono M, Fukushima H, Hosoi F, Yano H, Maruyama Y, et al. Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells. Mol Cancer Ther. 2007;6:2310–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, et al. Response to fluorouracil therapy in cancer patients; the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol. 1995;13:1663–01670.PubMedGoogle Scholar
  42. 42.
    Takayama A, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression of Hu-IFN-alpha R2 chain of Type 1 interferon receptor in human hepatocellular carcinoma and non-cancerous tissues. Int J Mol Med. 2000;6:621–7.PubMedGoogle Scholar
  43. 43.
    Kondo M, Nagano H, Sakon M, Yamamoto H, Morimoto O, Arai I, et al. Expression of interferon alpha/beta receptor in human hepatocellular carcinoma. Int J Oncol. 2000;17:83–8.PubMedGoogle Scholar
  44. 44.
    Kaido T, Macury C, Gresser I. Host CD4+ T lymphocytes are required for the synergistic action of IFN alpha/beta and adoptively transferred immune cells. Int J Cancer. 1994;57:538–43.CrossRefPubMedGoogle Scholar
  45. 45.
    Lindahl P, Leary P, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA. 1972;69:721–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Uno K, Shimizu S, Ido M, Naito K, Inaba K, Oku T, et al. Direct and indirect effect of interferon on in vivo murine tumor growth. Cancer Res. 1985;45:1320–7.PubMedGoogle Scholar
  47. 47.
    Levine AJ, Monmand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:435–56.CrossRefGoogle Scholar
  48. 48.
    Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78:703–11.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Satoru Hagiwara
    • 1
  • Masatoshi Kudo
    • 1
    Email author
  • Kazuomi Ueshima
    • 1
  • Hobyung Chung
    • 1
  • Mami Yamaguchi
    • 1
  • Masahiro Takita
    • 1
  • Seiji Haji
    • 2
  • Masatomo Kimura
    • 3
  • Tokuzo Arao
    • 4
  • Kazuto Nishio
    • 4
  • Ah-Mee Park
    • 5
  • Hiroshi Munakata
    • 5
  1. 1.Division of Gastroenterology and Hepatology, Department of Internal MedicineKinki University School of MedicineŌsakasayamaJapan
  2. 2.Department of SurgeryKinki University School of MedicineŌsakasayamaJapan
  3. 3.Department of PathologyKinki University School of MedicineŌsakasayamaJapan
  4. 4.Department of Genome BiologyKinki University School of MedicineŌsakasayamaJapan
  5. 5.Department of BiochemistryKinki University School of MedicineŌsakasayamaJapan

Personalised recommendations